A Phase 4 interventional study of Ocrelizumab in Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis, sponsored by Hoffmann-La Roche. Active, not recruiting at 17 sites in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 8th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 4, and was the 9th registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 8 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 60 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 184 across the 10 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche: 2 open now, 8 under way, 4 of them phase 3. Of 4 finished, 4 (100%) have results posted.
Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 4, and was the 10th registered.
Hoffmann-La Roche’s Multiple Sclerosis, Chronic Progressive studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 12 in Multiple Sclerosis, Chronic Progressive:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks).
Drug: Ocrelizumab
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks).
Drug: Ocrelizumab
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Also known as: OCREVUS®, RO4964913
RMS Cohort: Annualized Protocol-defined Relapse Rate
Time frame: Up to approximately 1.6 years
PPMS Cohort: B-cell Levels in Blood
Time frame: Up to Week 48
PPMS Cohort: Percentage of Participants Achieving Cluster of Differentiation 19 (CD19+) B-cell Levels of <10 Cells/Microliter (μL) at Week 48
Time frame: At Week 48
RMS Cohort: Percentage of Participants Who Have No Evidence of Disease Activity (NEDA3) During a 48-week Period
Time frame: Up to Week 48
RMS Cohort: Percentage of Relapse-free Participants by Week 48
Time frame: Up to Week 48
RMS Cohort: Percentage of Participants Who Have NEDA3 During a 24-week Period
Time frame: Up to Week 24
RMS Cohort: Total Number of T1 Gadolinium (Gd)-enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI)
Time frame: Up to Week 48
RMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI
Time frame: Up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in the Concentration of Serum Neurofilament Light Chain (Nfl)
Time frame: Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral \[or mental\]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability.
Time frame: Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful.
Time frame: Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful.
Time frame: Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Time frame: Baseline, Week 48
RMS and PPMS Cohorts: Serum Concentration of Ocrelizumab
Time frame: Up to Week 48
RMS Cohort: B-cell Levels in Blood
Time frame: Up to Week 48
RMS Cohort: Percentage of Participants Achieving CD19+ B-cell Levels of <10 cells/μL at Week 48
Time frame: At Week 48
PPMS Cohort: Total Number of T1 Gd-enhancing Lesions as Detected by Brain MRI at Week 24 and Week 48
Time frame: Week 24 and Week 48
PPMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI at Week 24 and Week 48
Time frame: Week 24 and Week 48
RMS and PPMS Cohorts: Number of Participants With Adverse Events (AEs)
Time frame: Up to approximately 1.8 years
RMS and PPMS Cohorts: Change from Baseline in T-cell Level
Time frame: Up to approximately 1.8 years
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior.
Time frame: Up to approximately 1.8 years
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Chronic Progressive →